Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Chronic kidney disease
•
Nephrology
•
Endocrinology
•
Bone and Calcium Disorders
Is there a role for monitoring PTH levels in patients with advanced chronic kidney disease who are receiving denosumab to assess for adynamic bone disease?
Related Questions
Do you recommend parathyroid imaging testing for patients with recurrent nephrolithiasis who are incidentally found to have an elevated PTH but who do not have hypercalciuria, hypercalcemia, hypovitaminosis D, or chronic kidney disease?
What treatment options would you consider for a young patient with limited mobility, low bone mass and multiple vertebral compression fractures who is on dialysis for advanced kidney disease?
Would you stop denosumab in a patient with chronic kidney disease if they develop asymptomatic hypocalcemia after the injection?
Would you expect cinacalcet to lower calcium levels in a patient with Familial Hypocalciuric Hypercalcemia (FHH)?
Is there a role for calcitriol in dialysis patients regardless of PTH level?
How do you choose between spironolactone and finerenone for patients with proteinuric diabetic kidney disease and heart failure?
How do you approach hematuria in a patient with diabetic nephropathy?
Are recurrent UTIs a contraindication to SGLT2i use?
Do you routinely check a TSH level in patients with recurrent kidney stones who have hypercalciuria of unknown cause?
What is the optimal management of pain and loss of function due to pathologic compression fractures?
